(Medscape Medical News) Feb 17, 2017 - For the first time in decades, there is a major advance in the second-line treatment of patients with advanced urothelial carcinoma whose disease has recurred or progressed after initial chemotherapy, according to new trial results published today in the New England Journal of Medicine.

(Genentech) Feb 17, 2017 - Genentech, a member of the Roche Group, today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell...